Advanced Medical Solutions Group plc
(“AMS” or the “Group”)
Full Year 2025 Trading Update
~ Strong growth in line with expectations, driven by key surgical product categories ~
Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the innovative tissue-healing medical device company delivering high-performing solutions for better patient outcomes, today announces a trading update for the twelve months ended 31 December 2025.
The Group expects to report full year 2025 revenues of approximately £228.5 million (2024: £177.5 million), EBITDA of £49.5 – £50.0 million (2024: £40.2 million), and the Board is confident of meeting market expectations. Its performance was driven by continued strong growth across key surgical product categories and a good recovery in its Woundcare business, offsetting some elements of destocking in the Peters Surgical B2B business.
The integration of Peters Surgical and Syntacoll remains on track. Commercial synergies contributed positively during the year with operational synergies are on track to be realised during 2027 onwards.
Notice of Results:
The Group intends to announce its full year results for the year ended 31 December 2025 on 18 March 2026.
Chris Meredith, Chief Executive Officer of AMS, said: “Our surgical business has recorded another period of strong performance, and we have also benefited from the restructuring of our woundcare franchise. Our portfolio is now broader and stronger than at any point in the Group’s history, and our pipeline includes a number of exciting and significant opportunities for future growth. The integration of Peters Surgical has accelerated the expansion of our geographic footprint, and our plans for further penetration into the US market are well advanced. We remain confident in delivering another strong performance in 2026 and over the long-term, supported by the sustained momentum across the business.”